Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC
This article was originally published in The Gray Sheet
Executive Summary
Coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have age-related macular degeneration and occult lesions with no classic choroidal neovascularization (CNV) should be restricted to those with small lesions, according to several MCAC panel members
You may also be interested in...
Off-Label Photodynamic Therapy Coverage Extended To AMD Population
Clinical trial subgroup analyses showing the ability of lesion size to predict patient benefit helped convince CMS to expand national Medicare coverage of QLT/Novartis' Visudyne (verteporfin)
Off-Label Photodynamic Therapy Coverage Extended To AMD Population
Clinical trial subgroup analyses showing the ability of lesion size to predict patient benefit helped convince CMS to expand national Medicare coverage of QLT/Novartis' Visudyne (verteporfin)
Evidence-Based Medicine Chasm: Can CMS, Industry Find Common Ground?
CMS' growing emphasis on evidence-based medicine to inform reimbursement decisions increasingly will lead manufacturers to conduct "high-quality" clinical trials, according to Chief Medical Officer Sean Tunis